[Hyperkalemia, heart failure and reduced renal function].
Bugge
Jan Fredrik
JF
Avdeling for anestesiologi, Akuttklinikken, Oslo universitetssykehus, Rikshospitalet, Postboks 4950 Nydalen, 0424 Oslo, Norway. jan.fredrik.bugge@oslo-universitetssykehus.no
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D051437:Renal Insufficiency / Q000139:chemically induced*; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists